ofloxacin has been researched along with Pneumonia, Bacterial in 117 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Pneumonia, Bacterial: Inflammation of the lung parenchyma that is caused by bacterial infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A possible case of levofloxacin-induced thrombocytopenia is reported." | 7.77 | Possible case of levofloxacin-induced thrombocytopenia. ( Liu, CY; Salloum, R; Weise, AM, 2011) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 7.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| " More patients treated with levofloxacin than with solithromycin experienced treatment-emergent adverse events (TEAEs) during the study (45." | 6.78 | Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. ( Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D, 2013) |
| "Levofloxacin is a fluoroquinolone with extensive renal elimination and enhanced penetration into lungs and Pseudomonas aeruginosa (PA) biofilms." | 6.73 | Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007) |
| "A possible case of levofloxacin-induced thrombocytopenia is reported." | 3.77 | Possible case of levofloxacin-induced thrombocytopenia. ( Liu, CY; Salloum, R; Weise, AM, 2011) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 3.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| "This study was conducted to evaluate the activity of levofloxacin in comparison with a range of antibacterial agents against recent isolates obtained consecutively from patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB) during the period 1995 to 1996." | 3.70 | Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. ( Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G, 1999) |
| " More patients treated with levofloxacin than with solithromycin experienced treatment-emergent adverse events (TEAEs) during the study (45." | 2.78 | Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. ( Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D, 2013) |
| " Nausea, vomiting, and diarrhoea were the most frequently reported adverse events." | 2.74 | Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. ( Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M, 2009) |
| "Levofloxacin is a fluoroquinolone with extensive renal elimination and enhanced penetration into lungs and Pseudomonas aeruginosa (PA) biofilms." | 2.73 | Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007) |
| " There were no statistically significant differences between the treatment groups with regard to drug-related adverse events." | 2.72 | Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. ( Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI, 2006) |
| " This subgroup analysis attempted to compare the safety and efficacy of a short-course levofloxacin regimen with traditional levofloxacin dosing for PSI Class III/IV patients." | 2.72 | Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. ( Kahn, JB; Khashab, MM; Shorr, AF; Tennenberg, AM; Xiang, JX, 2006) |
| " These differences can pose challenges in developing appropriate dosing guidelines." | 2.72 | Do intensive care patients need an individualized dosing regimen for levofloxacin? ( Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) |
| "42 mL/min/kg]), leading to a shorter elimination half-life (5." | 2.71 | Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ( Baldassarre, M; Brollo, L; Cusenza, A; Di Qual, E; Furlanut, M; Pea, F, 2003) |
| "Levofloxacin was administered as an infusion of 500 mg/h for 1." | 2.71 | Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. ( Corrado, M; Drusano, GL; Fowler, C; Kahn, J; Preston, SL; Weisinger, B, 2004) |
| "An intensive care unit and a clinical pharmacokinetic laboratory in two university hospitals." | 2.71 | Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Djabarouti, S; Rimmelé, T; Saux, MC, 2005) |
| "Levofloxacin may produce a faster clinical response than older macrolides, allowing for shorter hospital stay." | 2.71 | Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. ( Carratalà, J; Dorca, J; Fernández-Sabé, N; Gudiol, F; Manresa, F; Mykietiuk, A; Verdaguer, R, 2005) |
| "One moxifloxacin-treated patient had sustained monomorphic VT (> 30 s), and one levofloxacin-treated patient had torsade de pointes." | 2.71 | A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. ( Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS, 2005) |
| " Drug-related adverse events were reported in 5." | 2.68 | A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. ( Dunbar, L; File, TM; Kohler, R; Kojak, C; Player, R; Rubin, A; Segreti, J; Williams, RR, 1997) |
| "Levofloxacin is a fluoroquinolone that has a broad spectrum of activity against several causative bacterial pathogens of community-acquired pneumonia (CAP)." | 2.46 | Levofloxacin in the treatment of community-acquired pneumonia. ( Elkhatib, WF; Noreddin, AM, 2010) |
| "For levofloxacin-treated CAP patients with P." | 2.43 | Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006) |
| " Subsequently, a neutropenic murine pneumonia model with simulated clinical dosing exposures was used to validate our quantitative assessment of combined killing." | 1.36 | Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. ( Hou, J; Ledesma, KR; Prince, RA; Singh, R; Tam, VH; Yuan, Z, 2010) |
| "Amoxicillin was prescribed in 108 cases, fluoroquinolone in 24 cases, macrolide in 18 cases." | 1.36 | [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. ( Bernardin, G; Cua, E; de Salvador, F; Dellamonica, J; Hyvernat, H; Landraud, L; Risso, K; Roger, PM; Vassallo, M, 2010) |
| "pneumoniae serotype K1, complicated by septic shock and multiple organ dysfunction." | 1.35 | Rapidly fatal bacteremic pneumonia caused by Klebsiella pneumoniae with K1 hypermucoviscosity phenotype in a previously healthy young man receiving levofloxacin treatment. ( Chi, CL; Chuang, TY; Hsueh, PR; Lee, SW; Lin, CJ; Lin, TL; Liu, AY; Wang, JT, 2009) |
| "He was suffering from HLA-B27 positive spondylarthritis and stable diabetes mellitus." | 1.34 | [Pneumonia with bacteremia due to Yersinia enterocolitica in a diabetic patient carrying HLA-B27]. ( Girszyn, N; Kerleau, JM; Lefebvre, S; Levesque, H; Marie, I; Robaday, S, 2007) |
| " Adverse events were mild." | 1.33 | [Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients]. ( Chazan, R; Grabczak, M; Karwat, KJ, 2006) |
| " Considering the major pharmacodynamic determinants for the concentration-dependent bactericidal activity of levofloxacin as applicable at the urinary level (CU/MIC of >12." | 1.32 | Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ( Baldassarre, M; Brollo, L; Di Qual, E; Furlanut, M; Nascimben, E; Pavan, F; Pea, F, 2003) |
| "Levofloxacin is an additional option as monotherapy for the treatment of CAP." | 1.31 | Oral levofloxacin in the treatment of community-acquired pneumonia. ( Idrahim, KY; Lima Nicodemo, E; Nicodemo, AC, 2000) |
| "We evaluated the in vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia using a susceptible strain and one with low-level resistance (MIC/MBC of levofloxacin: 0." | 1.31 | In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. ( Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.85) | 18.7374 |
| 1990's | 11 (9.40) | 18.2507 |
| 2000's | 82 (70.09) | 29.6817 |
| 2010's | 23 (19.66) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zueva, LB | 1 |
| Oldach, D | 2 |
| Clark, K | 1 |
| Schranz, J | 1 |
| Das, A | 1 |
| Craft, JC | 1 |
| Scott, D | 1 |
| Jamieson, BD | 1 |
| Fernandes, P | 1 |
| Wang, JY | 1 |
| Lee, CH | 1 |
| Yu, MC | 1 |
| Lee, MC | 1 |
| Lee, LN | 1 |
| Wang, JT | 2 |
| Zhang, D | 1 |
| Gomez, JE | 1 |
| Chien, JY | 1 |
| Haseley, N | 1 |
| Desjardins, CA | 1 |
| Earl, AM | 1 |
| Hsueh, PR | 3 |
| Hung, DT | 1 |
| Llop, CJ | 1 |
| Tuttle, E | 1 |
| Tillotson, GS | 1 |
| LaPlante, K | 1 |
| File, TM | 4 |
| Tanaseanu, C | 2 |
| Bergallo, C | 2 |
| Teglia, O | 2 |
| Jasovich, A | 2 |
| Oliva, ME | 2 |
| Dukart, G | 2 |
| Dartois, N | 3 |
| Cooper, CA | 2 |
| Gandjini, H | 3 |
| Mallick, R | 2 |
| Rodríguez-Martínez, JM | 1 |
| Pichardo, C | 1 |
| García, I | 1 |
| Pachón-Ibañez, ME | 1 |
| Docobo-Pérez, F | 1 |
| Pascual, A | 1 |
| Pachón, J | 1 |
| Martínez-Martínez, L | 1 |
| Green, O | 1 |
| Murray, P | 1 |
| Gea-Banacloche, JC | 1 |
| Lentnek, A | 1 |
| de Wouters, L | 1 |
| Zlocowski, JC | 1 |
| Cooper, A | 2 |
| Castaing, N | 2 |
| Peterson, J | 1 |
| Yektashenas, B | 1 |
| Fisher, AC | 2 |
| Riabkova, EL | 1 |
| Kozlov, RS | 1 |
| Beloborodov, VB | 1 |
| Rapp, RP | 1 |
| Milutinovic, S | 1 |
| Calistru, PI | 1 |
| Strausz, J | 1 |
| Zolubas, M | 1 |
| Chernyak, V | 1 |
| Torralba, MÁ | 1 |
| Matía, M | 1 |
| Gómez del Valle, C | 1 |
| Pérez-Calvo, JI | 1 |
| Yuan, Z | 1 |
| Ledesma, KR | 1 |
| Singh, R | 1 |
| Hou, J | 1 |
| Prince, RA | 1 |
| Tam, VH | 1 |
| Roger, PM | 1 |
| Risso, K | 1 |
| Hyvernat, H | 1 |
| Landraud, L | 1 |
| Vassallo, M | 1 |
| Dellamonica, J | 1 |
| de Salvador, F | 1 |
| Cua, E | 1 |
| Bernardin, G | 1 |
| Chuang, TY | 2 |
| Lin, CJ | 2 |
| Chi, CL | 1 |
| Liu, AY | 1 |
| Lee, SW | 2 |
| Lin, TL | 1 |
| Blasi, F | 2 |
| Noreddin, AM | 1 |
| Elkhatib, WF | 1 |
| Mokabberi, R | 1 |
| Haftbaradaran, A | 1 |
| Ravakhah, K | 1 |
| Hess, G | 1 |
| Hill, JW | 1 |
| Raut, MK | 1 |
| Mody, S | 1 |
| Schein, JR | 2 |
| Chen, CC | 1 |
| Bobyleva, ZD | 1 |
| Leshchenko, IV | 1 |
| Wispelwey, B | 1 |
| Schafer, KR | 1 |
| Le Falher, G | 1 |
| Makinson, A | 1 |
| Eden, A | 1 |
| Lesnik, A | 1 |
| Le Moing, V | 1 |
| Reynes, J | 1 |
| Salloum, R | 1 |
| Liu, CY | 1 |
| Weise, AM | 1 |
| Gregorini, M | 1 |
| Castello, M | 1 |
| Rampino, T | 1 |
| Esposito, P | 1 |
| Rosso, R | 2 |
| Borroni, G | 1 |
| Dal Canton, A | 1 |
| Galstian, GM | 1 |
| Drokov, MIu | 1 |
| Katrysh, SA | 1 |
| Kliasova, GA | 1 |
| Giliazitdinova, EA | 1 |
| Karpova, TI | 1 |
| Marakusha, BI | 1 |
| Tartakovskiĭ, IS | 1 |
| Chuang, CP | 1 |
| Jong, YS | 1 |
| Chen, WJ | 1 |
| Biedenbach, DJ | 1 |
| Farrell, DJ | 1 |
| Flamm, RK | 1 |
| Liverman, LC | 1 |
| McIntyre, G | 1 |
| Jones, RN | 2 |
| Mori, N | 1 |
| Ishii, Y | 1 |
| Tateda, K | 1 |
| Kimura, S | 1 |
| Kouyama, Y | 1 |
| Inoko, H | 1 |
| Mitsunaga, S | 1 |
| Yamaguchi, K | 1 |
| Yoshihara, E | 1 |
| Lee, JH | 1 |
| Kim, SW | 1 |
| Kim, JH | 1 |
| Ryu, YJ | 1 |
| Chang, JH | 1 |
| Ramirez, JA | 2 |
| Cooper, AC | 1 |
| Wiemken, T | 1 |
| Gardiner, D | 1 |
| Babinchak, T | 1 |
| Dong, LY | 1 |
| Wang, CY | 1 |
| Wu, CQ | 1 |
| Jiang, Q | 1 |
| Zhang, ZF | 1 |
| Ruiz, A | 1 |
| Falguera, M | 1 |
| Sacristán, O | 1 |
| Vallverdú, M | 1 |
| Cabré, X | 1 |
| Pérez, J | 1 |
| Ferrer, G | 1 |
| Iakovlev, SV | 1 |
| Iakovlev, VP | 1 |
| Geijo Martínez, MP | 1 |
| Díaz de Tuesta Chow-Quan, AM | 1 |
| Herranz, CR | 1 |
| Gómez Criado, C | 1 |
| Dimas Nuñez, JF | 1 |
| Saiz García, F | 1 |
| Malcolm, C | 1 |
| Marrie, TJ | 3 |
| West, M | 1 |
| Boulanger, BR | 1 |
| Fogarty, C | 1 |
| Tennenberg, A | 1 |
| Wiesinger, B | 1 |
| Oross, M | 1 |
| Wu, SC | 3 |
| Fowler, C | 2 |
| Morgan, N | 1 |
| Kahn, JB | 3 |
| Burgmann, H | 1 |
| Mayer, B | 1 |
| Lukas, A | 1 |
| Kumbein, F | 1 |
| Oberbauer, R | 1 |
| Pea, F | 3 |
| Di Qual, E | 2 |
| Cusenza, A | 1 |
| Brollo, L | 2 |
| Baldassarre, M | 2 |
| Furlanut, M | 3 |
| Paladino, JA | 1 |
| Sunderlin, JL | 1 |
| Forrest, A | 1 |
| Schentag, JJ | 1 |
| Erard, V | 2 |
| Lamy, O | 2 |
| Bochud, PY | 1 |
| Bille, J | 1 |
| Cometta, A | 2 |
| Calandra, T | 2 |
| Pavan, F | 1 |
| Nascimben, E | 1 |
| Drusano, GL | 1 |
| Preston, SL | 1 |
| Corrado, M | 1 |
| Weisinger, B | 1 |
| Kahn, J | 2 |
| Dunbar, LM | 1 |
| Khashab, MM | 3 |
| Zadeikis, N | 3 |
| Xiang, JX | 3 |
| Tennenberg, AM | 5 |
| Martinez, FJ | 1 |
| Pohjola-Sintonen, S | 1 |
| Kannisto, M | 1 |
| Uriarte, SM | 1 |
| Molestina, RE | 1 |
| Miller, RD | 1 |
| Bernabo, J | 1 |
| Farinati, A | 1 |
| Eiguchi, K | 1 |
| Summersgill, JT | 1 |
| Alvarez Lerma, F | 1 |
| Milkovich, G | 1 |
| Wasserfallen, JB | 1 |
| Zervos, M | 1 |
| Mandell, LA | 1 |
| Vrooman, PS | 1 |
| Andrews, CP | 1 |
| McIvor, A | 1 |
| Abdulla, RH | 1 |
| de Caprariis, PJ | 1 |
| Knirsch, CA | 1 |
| Amsden, GW | 1 |
| Niederman, MS | 3 |
| Lode, H | 2 |
| Querol-Ribelles, JM | 1 |
| Tenías, JM | 1 |
| Querol-Borrás, JM | 1 |
| Labrador, T | 1 |
| Nieto, A | 1 |
| González-Granda, D | 1 |
| Martínez, I | 1 |
| Boselli, E | 1 |
| Breilh, D | 1 |
| Rimmelé, T | 1 |
| Djabarouti, S | 1 |
| Saux, MC | 1 |
| Chassard, D | 1 |
| Allaouchiche, B | 1 |
| Lüthje, P | 1 |
| Nurmi, I | 1 |
| Nyyssönen, T | 1 |
| Carratalà, J | 2 |
| Fernández-Sabé, N | 2 |
| Ortega, L | 1 |
| Castellsagué, X | 1 |
| Rosón, B | 1 |
| Dorca, J | 2 |
| Fernández-Agüera, A | 1 |
| Verdaguer, R | 2 |
| Martínez, J | 1 |
| Manresa, F | 2 |
| Gudiol, F | 2 |
| Mandell, L | 1 |
| Shorr, AF | 3 |
| Susla, GB | 1 |
| Kollef, MH | 2 |
| Jackson, WL | 1 |
| Ramage, AS | 1 |
| Mykietiuk, A | 1 |
| Skrepnek, GH | 1 |
| Armstrong, EP | 1 |
| Malone, DC | 1 |
| Ramachandran, S | 1 |
| Torres, A | 3 |
| Leroy, O | 1 |
| Saux, P | 1 |
| Bédos, JP | 2 |
| Caulin, E | 1 |
| Moine, P | 1 |
| Milbrandt, EB | 1 |
| Angus, DC | 1 |
| Samsa, GP | 1 |
| Matchar, DB | 1 |
| Harnett, J | 1 |
| Wilson, J | 1 |
| Morganroth, J | 1 |
| Dimarco, JP | 1 |
| Anzueto, A | 2 |
| Choudhri, S | 2 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Pearle, J | 1 |
| Restrepo, MI | 1 |
| Heyder, A | 1 |
| Choudhri, SH | 1 |
| Alvarez-Lerma, F | 1 |
| Grau, S | 1 |
| Alvarez-Beltrán, M | 1 |
| Davis, NB | 1 |
| Carranza González, R | 1 |
| Tena Gómez, D | 1 |
| Prieto Gómez, E | 1 |
| Barberá Farré, JR | 1 |
| Fernández Cenjor, J | 1 |
| Tayab, ZR | 1 |
| Hochhaus, G | 1 |
| Kaufmann, S | 1 |
| Jäger, D | 1 |
| Barth, J | 1 |
| Wenisch, C | 1 |
| Krause, R | 1 |
| Széll, M | 1 |
| Laferl, H | 1 |
| Bassetti, M | 1 |
| Righi, E | 1 |
| Mannelli, S | 1 |
| Di Biagio, A | 1 |
| Fasce, R | 1 |
| Pallavicini, FB | 1 |
| Marchetti, F | 1 |
| Viscoli, C | 1 |
| Karwat, KJ | 1 |
| Grabczak, M | 1 |
| Chazan, R | 1 |
| Lee, CKK | 1 |
| Boyle, MP | 1 |
| Diener-West, M | 1 |
| Brass-Ernst, L | 1 |
| Noschese, M | 1 |
| Zeitlin, PL | 1 |
| Girszyn, N | 1 |
| Kerleau, JM | 1 |
| Robaday, S | 1 |
| Lefebvre, S | 1 |
| Marie, I | 1 |
| Levesque, H | 1 |
| Dimopoulos, G | 1 |
| Grupper, M | 1 |
| Potasman, I | 1 |
| Ye, X | 1 |
| Sikirica, V | 2 |
| Grant, R | 2 |
| Zarotsky, V | 1 |
| Doshi, D | 2 |
| Benson, CJ | 1 |
| Riedel, AA | 1 |
| Lloyd, A | 1 |
| Holman, A | 1 |
| Evers, T | 1 |
| Garau, J | 1 |
| Arvis, P | 1 |
| Carlet, J | 1 |
| Kureishi, A | 1 |
| Le Berre, MA | 1 |
| Winter, J | 1 |
| Read, RC | 1 |
| Schein, J | 1 |
| Janagap-Benson, C | 1 |
| Olson, W | 1 |
| Gaillat, J | 1 |
| Bru, JP | 1 |
| Sedallian, A | 1 |
| Portier, H | 1 |
| May, T | 1 |
| Proust, A | 1 |
| Baty, V | 1 |
| Hoen, B | 1 |
| Schuhmacher, H | 1 |
| Amiel, C | 1 |
| Reyrolle, M | 1 |
| Garin, H | 1 |
| Canton, P | 1 |
| Segreti, J | 1 |
| Dunbar, L | 1 |
| Player, R | 1 |
| Kohler, R | 1 |
| Williams, RR | 2 |
| Kojak, C | 2 |
| Rubin, A | 1 |
| Ishida, H | 1 |
| Ishida, Y | 1 |
| Kurosaka, Y | 1 |
| Otani, T | 1 |
| Sato, K | 1 |
| Kobayashi, H | 1 |
| Norrby, SR | 1 |
| Petermann, W | 1 |
| Willcox, PA | 1 |
| Vetter, N | 1 |
| Salewski, E | 1 |
| DiPersio, JR | 1 |
| Barrett, T | 1 |
| Doern, GV | 1 |
| Pfaller, MA | 1 |
| Casellas, JM | 1 |
| Gilardoni, M | 1 |
| Tome, G | 1 |
| Goldberg, M | 1 |
| Ivanovic, S | 1 |
| Orduna, M | 1 |
| Dolmann, A | 1 |
| Ascoli, M | 1 |
| Ariza, H | 1 |
| Montero, JM | 1 |
| Sefton, AM | 1 |
| Maskell, JP | 1 |
| Williams, JD | 1 |
| Arancibia, F | 1 |
| Maldonado, A | 1 |
| Belousov, IuB | 1 |
| Efremenkova, OV | 1 |
| Sokolov, AV | 1 |
| Tishenkova, IF | 1 |
| Aviles, RJ | 1 |
| Dockrell, DH | 1 |
| Thompson, RL | 1 |
| Nicodemo, AC | 1 |
| Lima Nicodemo, E | 1 |
| Idrahim, KY | 1 |
| Hammerschlag, MR | 1 |
| Roblin, PM | 1 |
| Rittenhouse, BE | 1 |
| Stinnett, AA | 1 |
| Dulisse, B | 1 |
| Henke, CJ | 1 |
| Potter, L | 1 |
| Parasuraman, B | 1 |
| Martens, LL | 1 |
| Joly-Guillou, ML | 1 |
| Wolff, M | 1 |
| Farinotti, R | 1 |
| Bryskier, A | 1 |
| Carbon, C | 1 |
| Lau, CY | 1 |
| Wheeler, SL | 1 |
| Wong, CJ | 1 |
| Feagan, BG | 1 |
| Shah, PM | 1 |
| Manzella, J | 1 |
| Benenson, R | 1 |
| Pellerin, G | 1 |
| Kellogg, J | 1 |
| Bell, T | 1 |
| Robertson, M | 1 |
| Pope, D | 1 |
| Simsir, A | 1 |
| Forest, G | 1 |
| Henry, M | 1 |
| Scheen, AJ | 1 |
| Remacha Esteras, M | 1 |
| Herrera Rubio, J | 1 |
| Parra Parra, I | 1 |
| Budanov, SV | 1 |
| Vasil'ev, AN | 1 |
| Smirnova, LB | 1 |
| Lin, Y | 1 |
| Su, W | 1 |
| Xu, Z | 1 |
| Bai, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia[NCT01168713] | Phase 2 | 132 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00079885] | Phase 3 | 430 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00081575] | Phase 3 | 434 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia[NCT00236834] | Phase 3 | 438 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Tr[NCT00431678] | Phase 3 | 738 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
15 reviews available for ofloxacin and Pneumonia, Bacterial
| Article | Year |
|---|---|
[Present aspects and prospects of levofloxacin use in therapy of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
[Clinical positioning of levofloxacin in the treatment of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross In | 2009 |
Levofloxacin in the treatment of community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Humans; Levofl | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired | 2010 |
[Levofloxacin in the treatment of respiratory infections].
Topics: Acute Disease; Anti-Infective Agents; Bronchitis, Chronic; Clinical Trials as Topic; Drug Resistance | 2002 |
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
Topics: Administration, Oral; Anti-Infective Agents; Area Under Curve; Biological Availability; Case-Control | 2004 |
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infecti | 2004 |
New insights in the treatment by levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resista | 2004 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; M | 2005 |
Levofloxacin in the treatment of ventilator-associated pneumonia.
Topics: Anti-Infective Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Of | 2006 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re | 2006 |
[Clinical experience of levofloxacin in community acquired pneumonia].
Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxac | 1999 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec | 2000 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec | 2001 |
46 trials available for ofloxacin and Pneumonia, Bacterial
| Article | Year |
|---|---|
[Zoflox, an antibacterial drug, in treatment of infectious pathologic processes in the lower respiratory tract complicating acute respiratory viral infection in elderly patients].
Topics: Acute Disease; Aged; Ambulatory Care; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Femal | 2012 |
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Double-Blind Method; Fema | 2013 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haem | 2009 |
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination | 2008 |
Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis.
Topics: Aged; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Female; Humans; | 2009 |
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diarrhea; Dose-Respon | 2009 |
Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Doxycycline; | 2010 |
High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hum | 2012 |
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blin | 2012 |
[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithro | 2002 |
[Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Clavulanic Acid; Commun | 2002 |
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combin | 2003 |
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
Topics: Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Critical Illness; Cross Infection | 2003 |
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Fluoroquinolones; | 2003 |
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Dose-Response R | 2004 |
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Cross Infection; Female; Fl | 2004 |
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Inf | 2004 |
Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients.
Topics: Anti-Infective Agents; Confidence Intervals; Critical Illness; Dose-Response Relationship, Drug; Dru | 2004 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azi | 2004 |
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Administrati | 2004 |
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis | 2004 |
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Azithromycin; Canada; Ceftriaxone; Community-Acqu | 2004 |
Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cohort Studies; Community-Acquired Infecti | 2005 |
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Capillary Permeability; Community-Acquired Infections; Creatinine; Crit | 2005 |
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Commun | 2005 |
Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Cross Infe | 2005 |
Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Female; Humans; Legionnaires' Disease; Levo | 2005 |
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefotaxime; Chi-Square Distribution; Community-Acquired Infectio | 2005 |
A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Costs and Cos | 2005 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorb | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double | 2006 |
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Drug Administration Schedule | 2006 |
Do intensive care patients need an individualized dosing regimen for levofloxacin?
Topics: Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Levofloxacin; Male; M | 2006 |
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Dru | 2006 |
Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Gram-N | 2006 |
Levofloxacin pharmacokinetics in adult cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Le | 2007 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Co | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acqu | 2008 |
Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Clavulanic Acids; Community | 1994 |
Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Community-Acquire | 1996 |
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone | 1997 |
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Comm | 1998 |
[The importance of fluoroquinolones in treating pneumonia in the elderly].
Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Fluoroqu | 1999 |
An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Cefuroxime; Cephalosporins; Drug Costs; Evaluat | 2000 |
Predictors of symptom resolution in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gastro | 2000 |
56 other studies available for ofloxacin and Pneumonia, Bacterial
| Article | Year |
|---|---|
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; | 2015 |
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
Topics: Antitubercular Agents; Clone Cells; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Evolution, Mol | 2016 |
Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired I | 2017 |
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Colony Count, Microbial; Drug Res | 2008 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxa | 2008 |
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug R | 2002 |
[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infectio | 2010 |
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.
Topics: Acinetobacter baumannii; Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease | 2010 |
[Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Cohort Studies; Co | 2010 |
Rapidly fatal bacteremic pneumonia caused by Klebsiella pneumoniae with K1 hypermucoviscosity phenotype in a previously healthy young man receiving levofloxacin treatment.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacteremia; Bacterial Capsules; Bacterial Typing Techniq | 2009 |
Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Community-Acquired Infections | 2010 |
[Clinical features and delayed aftereffects of Legionellosis pneumonia during an epidemic outbreak].
Topics: Anti-Bacterial Agents; Azithromycin; Disease Outbreaks; Female; Humans; Legionellosis; Levofloxacin; | 2010 |
[Two cases of pulmonary gangrene in HIV-infected patients: favorable outcome without surgery].
Topics: Acetamides; Adult; Alcoholism; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gangre | 2011 |
Possible case of levofloxacin-induced thrombocytopenia.
Topics: Aged; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Female; Humans; Levofloxacin; Mouth Neoplasms | 2011 |
Erythema nodosum in kidney transplant recipient: a rare complication of pneumonia treatment.
Topics: Adult; Anti-Bacterial Agents; Erythema Nodosum; Female; Humans; Kidney Transplantation; Leg; Levoflo | 2012 |
[A case of legionellesis pneumonia verified by isolation of Legionella pneumophila serogroup 1 from bronchoalveolar lavage fluid treated with levofloxacine and tigecycline].
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; Humans; Legionella p | 2011 |
Rapidly fatal community-acquired pneumonia due to Klebsiella pneumoniae complicated with acute myocarditis and accelerated idioventricular rhythm.
Topics: Accelerated Idioventricular Rhythm; Acidosis, Lactic; Acute Disease; Community-Acquired Infections; | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; D | 2012 |
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western | 2012 |
[Protection and mechanism of Fagopyrum cymosum on lung injury in rats with Klebsiella pneumonia].
Topics: Animals; Chemokine CXCL2; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Fagopyrum; Immun | 2012 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azit | 2003 |
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydo | 2003 |
Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.
Topics: Adult; Aged; Biological Availability; Critical Illness; Dose-Response Relationship, Drug; Drug Admin | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Comb | 2004 |
[Equally whether the child's lung or chronically inflamed bronchi. Acute bacterial infections have to be terminated fast].
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 2004 |
[The rupture of both Achilles tendons as a complication from fluoroquinolone treatment].
Topics: Achilles Tendon; Dose-Response Relationship, Drug; Drug Administration Schedule; Finland; Fluoroquin | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluor | 2004 |
Missed Achilles tendon rupture due to oral levofloxacin: surgical treatment and result.
Topics: Achilles Tendon; Administration, Oral; Anti-Bacterial Agents; Diagnostic Errors; Humans; Levofloxaci | 2005 |
Summaries for patients. Can patients with pneumonia take their antibiotics at home?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Commun | 2005 |
Decisions about treating community-acquired pneumonia.
Topics: Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Hospitalization; Humans; Oflo | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infection | 2005 |
Monotherapy in severe community-acquired pneumonia: is it worthy?
Topics: Anti-Bacterial Agents; Cefotaxime; Community-Acquired Infections; Drug Therapy, Combination; Humans; | 2005 |
Levofloxacin for treatment of ventilator-associated pneumonia: putting the cart before the horse.
Topics: Anti-Bacterial Agents; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Ventilators, Mechanica | 2005 |
What's in a day?
Topics: Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Humans; Length of Stay; Ofloxaci | 2005 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
[Pneumonia by Corynebacterium pseudodiphteriticum: an infection to consider].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Corynebacte | 2006 |
[Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hospitalizati | 2006 |
[Pneumonia with bacteremia due to Yersinia enterocolitica in a diabetic patient carrying HLA-B27].
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Diabetes Mellitus, Type 2; HLA-B27 Antigen; Humans; Male; O | 2007 |
Antibiotics selection for bacteremic pneumonia.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactams; Dose-Response Relationship, Drug; Fluoroquinolones; | 2007 |
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; | 2008 |
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Ana | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Co | 2008 |
Legionella jordanis pneumonia unresponsive to fluoroquinolones in a non-immunocompromised host.
Topics: Aged; Anti-Infective Agents; Ceftriaxone; Drug Therapy, Combination; Erythromycin; Humans; Immunocom | 1997 |
In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.
Topics: Alginates; Animals; Anti-Infective Agents; Biofilms; Female; Glucuronic Acid; Guinea Pigs; Hexuronic | 1998 |
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Humans; Immunocompr | 1998 |
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Commun | 1999 |
Selection of resistant variants of respiratory pathogens by quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Le | 1999 |
52-year-old man with shortness of breath.
Topics: Anti-Infective Agents; Community-Acquired Infections; Diagnosis, Differential; Dyspnea; Humans; Male | 2000 |
Oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Hum | 2000 |
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections | 2000 |
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Unde | 2000 |
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxon | 2000 |
Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy.
Topics: Actinomycetales Infections; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antigens, Viral; An | 2001 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchit | 2000 |
[Bacteremic pneumonia due to Streptococcus equisimilis].
Topics: Aged; Anti-Infective Agents; Blood; Humans; Male; Ofloxacin; Pneumonia, Bacterial; Streptococcal Inf | 2001 |
Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Community-Acquired Infec | 2001 |